Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.73 |
| ▸ | OPRL1 | P41146 | 15/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7478459 | 0.97 | OPRM1 (0.69) | OPRM1OPRL1OPRK1 | |
| Hydrochloric Acid SCHEMBL7478467 | 0.97 | OPRM1 (0.69) | OPRM1OPRL1OPRK1 | |
| SCHEMBL7309717 | 0.84 | OPRM1 (0.53) | OPRM1OPRL1OPRK1 | |
| SCHEMBL7313869 | 0.84 | OPRM1 (0.56) | OPRM1OPRL1OPRK1 | |
| SCHEMBL6543224 | 0.84 | OPRM1 (0.53) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3410403 | 0.84 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL7514792 | 0.83 | OPRM1 (0.56) | OPRM1OPRL1OPRK1 | |
| SCHEMBL7312540 | 0.83 | OPRM1 (0.51) | OPRM1OPRL1OPRK1 | |
| Hydrochloric Acid SCHEMBL6543281 | 0.82 | OPRM1 (0.54) | OPRM1OPRL1OPRK1 | |
| SCHEMBL2834926 | 0.82 | OPRM1 (0.72) | OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | claimed |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| EP-1923391-A1 | Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them. | sanofi-aventis (FR) | 2008-05-21 | — | — | EP | disclosed |
| EP-1688416-A1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | Sanofi-Aventis (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-7060836-B2 | Lactams as tachykinin antagonists | PFIZER, INC (US) | 2006-06-13 | — | — | US | disclosed |
| US-7041679-B2 | Crystalline forms of osanetant | SANOFI-AVENTIS (FR) | 2006-05-09 | — | — | US | disclosed |
| EP-1156049-B1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | SANOFI AVENTIS (FR) | 2005-06-01 | — | — | EP | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PFIZER INC. | 2004-07-08 | — | — | US | disclosed |
| CN-1056605-C | Compounds as selective antagonists of human tachykinin III receptor and uses thereof | SANOFI CORP (FR) | 2000-09-20 | — | — | CN | disclosed |
| EP-1019373-A1 | NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000007987-A1 | CRYSTALLINE FORMS OF OSANETANT | SANOFI-SYNTHELABO (FR) | 2000-02-17 | — | — | WO | disclosed |
| US-5942523-A | NOVEL PIPERIDINE DERIVATIVES WHOSE SPECIFIC STRUCTURE INCLUDES AT POSITION 1 AN ALKYL CHAIN HAVING A 3,4-DICHLOROPHENYL GROUP ATTACHED; HIGH SELECTIVITY TO THE NK3 RECEPTOR; UNIT DOSAGE FORM; TREATING PSYCHIATRIC DISEASES | SANOFI (FR) | 1999-08-24 | — | — | US | disclosed |
| US-5741910-A | PIPERIDINE DERIVATIVE INTERMEDIATES | SANOFI (FR) | 1998-04-21 | — | — | US | disclosed |
| EP-0807111-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
| CN-1128756-A | Compounds as selective antagonists of the human tachykinin III receptor and uses thereof | SANOFI CORP (FR) | 1996-08-14 | — | — | CN | disclosed |
| WO-1996023787-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1996-08-08 | — | — | WO | disclosed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | OPRM1 703/4885OPRL1 61/4885OPRK1 156/4885 |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PROKR1, TACR2, TACR1 | OPRM1 66/4885OPRL1 31/4885OPRK1 15/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | OPRM1 703/4885OPRL1 61/4885OPRK1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.